WASABI METHOD / PROFESSIONAL RESOURCES
Women’s & Pelvic Health Shockwave Therapy Applications
Author: Wasabi Method | SWSNA
Medical reviewer: Adam Gavine, BHK, M.Chiro | Shockwave Trainer | International Medical Shockwave Advisor
Medical review date: 10/2026
Explore women’s pelvic health shockwave applications through the clinical questions that matter: What is the diagnosis? Which tissue is being considered? What does the evidence support? And how should treatment fit into a broader care plan?
This resource is intended for qualified healthcare professionals assessing lymphedema, painful lipedema, vulvodynia and stress urinary incontinence. Compare clinical objectives, focused and radial technologies, published research frameworks and safety considerations using Wasabi Method’s evidence-informed, manufacturer-neutral approach.
Explore professional shockwave training · Read the shockwave contraindications resource
Understanding Shockwave Therapy in Women’s Health
Extracorporeal shockwave therapy delivers acoustic energy from outside the body. Research in women’s health includes symptom-focused treatment of limb swelling and pain, persistent vulvar pain and urinary leakage. These are different clinical problems with different anatomical targets. Evidence for one application does not establish benefit for another.[1],[2],[3],[4],[5],[6],[7],[8]
Focused systems concentrate acoustic energy within a defined treatment region. Radial pressure-wave systems produce waves that spread from the applicator, with their greatest pressure near the surface. “Radial shockwave” is a common commercial term, but focused shockwaves and radial pressure waves are physically distinct. Reported energy, focal depth, applicator geometry and coupling influence what reaches the intended tissue.[1],[2]
Both technologies appear in relevant practice and research, but their representation and evidence vary by indication. The available studies do not establish an overall winner or prove that focused and radial devices are equivalent. Selection should consider the diagnosis, target depth, device-specific evidence and instructions for use. A lack of adequate comparative trials is not proof of equal efficacy.
Terminology at a Glance
| Term | Meaning on this page |
|---|---|
| Focused ESWT | Extracorporeal shockwaves concentrated within a device-dependent treatment region. |
| Radial pressure-wave therapy | Pressure waves spreading from a surface applicator, often marketed as radial shockwave therapy. |
| LI-ESWT / LiSWT | Low-intensity extracorporeal shockwave therapy. The abbreviation alone does not identify a generator or reproducible dose. |
| Energy flux density | A commonly reported parameter expressed in mJ/mm². It is not interchangeable with a radial device’s bar setting. |
| Lymphedema | Swelling associated with impaired lymphatic transport; distinct from lipedema. |
| Lipedema | A disorder involving disproportionate subcutaneous adipose tissue and symptoms such as tenderness; it may coexist with lymphatic dysfunction. |
| Vulvodynia | Vulvar pain lasting at least three months without a clear identifiable cause, following appropriate assessment.[9] |
| Stress urinary incontinence | Urine leakage with exertion, coughing or sneezing; distinct from urgency-predominant leakage. |
Diagnosis Before Device Selection
Accurate diagnosis is essential to treatment selection. It determines which research findings, treatment objectives and care pathway are relevant. Swelling, painful tissue, vulvar discomfort and urinary leakage require their own differential assessments.
Care may combine medical management, compression, rehabilitation, pelvic floor therapy, pain education and psychological or psychosexual support. A device should be selected around this plan. Training in shockwave delivery does not independently qualify a practitioner to diagnose vascular, oncological or pelvic disorders.
If diagnosis falls outside a practitioner’s scope or specialty, obtain assessment or referral from an appropriately qualified clinician. Shockwave treatment may be considered elective or adjunctive where appropriate. Elective status does not replace diagnostic clarity, lawful scope, patient selection or informed consent.
Explore Women’s & Pelvic Health Applications
Select an application to review assessment, anatomy, evidence, technology and care integration.
Lymphedema*
Common Empirically-Tested Clinical Use
Overview
Lymphedema involves impaired lymphatic drainage with swelling, tissue changes and potential functional limitations. Much of the clinical shockwave literature concerns breast cancer-related upper-limb lymphedema. That evidence should not automatically be generalised to primary lymphedema, lower-limb disease or all postoperative swelling.[2],[3]
The treatment objective is symptom and function improvement alongside established lymphedema care. Assessment should establish the cause, distribution and clinical stage of swelling and identify conditions requiring medical investigation before an elective intervention.
Anatomy and Treatment Targeting
Relevant structures include skin, subcutaneous tissues, superficial lymphatic pathways, areas of fibrosis and the regional anatomy affected by surgery or radiation. Document surgical history and tissue sensitivity. Treatment planning should distinguish a selected superficial tissue field from indiscriminate exposure of the axilla or chest wall.
Use consistent circumference or volume measurements, tissue examination and appropriate imaging or specialist assessment where indicated. Treatment near the chest requires particular attention to the acoustic path and underlying structures.
Illustrative Protocol Framework
Reference 2 provides a starting point for locating the original study methods. A reproducible framework must specify:
- Device model, generator type and applicator.
- Defined treatment field and the rationale for its selection.
- Pulse count, repetition rate in Hz and energy in the device’s reported units.
- Sessions per week, total sessions and concurrent decongestive treatment.
- Measurement methods and the original follow-up schedule.
No single device/applicator combination or transferable dose is established here. Review the full methods of the selected study before clinical application. Do not derive missing settings from an unrelated device or indication.
Technique and Care Integration
Position the limb with support and access to the intended field. Use coupling and contact pressure according to the device instructions and tissue condition. Coordinate with appropriately trained lymphedema clinicians, maintaining indicated compression, exercise, skin care and other decongestive measures.[2],[3]
Course of Care and Reassessment
Record baseline volume or circumference using a repeatable method, tissue symptoms, function and patient goals. Agree a finite review point, reassess tolerance during each session and repeat outcome measurements after the planned course. Keep measurement conditions consistent and document changes in compression or other treatment.
Stop or modify the plan if symptoms worsen or meaningful benefit is absent. New or rapidly changing swelling requires reassessment of the cause rather than automatic extension of treatment.
Safety and Further Education
Suspected cellulitis, thrombosis, unexplained swelling or possible cancer recurrence requires medical assessment. Previous cancer is not the same as a malignant tumour in the treatment field; oncology history and current status still require careful review.[1]
Review shockwave contraindications · Explore professional training
Painful Lipedema**
Exceptional / Expert Indication
Overview
Painful lipedema is associated with disproportionate adipose tissue distribution, tenderness and functional burden. It should be differentiated from uncomplicated obesity, isolated lymphedema and other causes of painful swelling. Some patients have overlapping conditions.
The clinical objective is symptom relief and improved activity within a broader care programme. Shockwaves should not be presented as a proven method of removing lipedema fat or curing the condition.[4],[5]
Anatomy and Treatment Targeting
Assessment considers the distribution of affected subcutaneous tissue, pressure sensitivity, bruising, skin integrity and functional limitations. Examine for coexisting oedema or vascular disease. Ultrasound or other investigations may assist a specialist assessment but should not be used to infer a treatment effect that was not measured.
Illustrative Protocol Framework
Research example: Novo Rigueiro and colleagues used radial ESWT over six sessions, delivered twice weekly.[4] The study abstract does not specify the complete device model, applicator, bar setting, pulse count or repetition rate. Those details must be confirmed from the full methods before any attempt to reproduce the study.
The postoperative study’s timing must not be treated as permission to start treatment after every liposuction procedure. Postoperative suitability requires surgeon involvement and review of the actual device-specific methods.[5]
Technique and Care Integration
Support the limb comfortably and use careful contact and coupling over sensitive tissue. Coordinate with the patient’s existing conservative or surgical team. Integrate treatment, where appropriate, with individualised activity, compression, rehabilitation and symptom-management strategies. Distinguish comfort-related improvement from a demonstrated structural change.
Course of Care and Reassessment
Track pain or tenderness, bruising, walking or activity tolerance, a consistent functional measure and patient goals. Reassess tolerance at each session and repeat baseline measures at the end of the agreed course. The six-week and three-month time points in reference 4 are research follow-ups, not a universal clinical schedule.
Stop for worsening bruising, persistent symptom escalation or skin injury. Refer unexplained asymmetry or acute swelling for diagnostic review.
Safety and Further Education
Assess bleeding risk, anticoagulant use, skin fragility, vascular concerns and any recent surgery. Do not change prescribed medication without the prescriber. Treatment pressure and exposure should not be escalated simply to provoke a stronger sensation.
Read the contraindications resource · Explore professional education
Vulvodynia***
Experimental Indication
Overview
Vulvodynia is vulvar pain lasting at least three months without a clear identifiable cause. Pain may be localised or generalised and provoked, spontaneous or mixed. Assessment should distinguish it from infection, dermatological disease, hormonal tissue changes and other identifiable causes of vulvar pain.[9]
The objective is reduced pain interference and improved daily or sexual function through individualised care. Shockwave therapy remains an emerging option and should not replace a diagnostic evaluation or established multidisciplinary management.
Anatomy and Treatment Targeting
Relevant anatomy includes the vulva, vestibule, perineal tissues, pelvic floor and nearby neurovascular structures. A qualified clinician may use examination and gentle cotton-swab mapping to characterise the pain distribution.[9] A painful point is not automatically a safe acoustic target.
External perineal delivery and intravaginal application are different procedures. Neither the route nor the applicator can be substituted without appropriate evidence, qualifications and device compatibility.
Illustrative Protocol Framework
The 2020 trial reported externally applied perineal ESWT with:[6]
- Technology: focused shockwave generator; verify the exact model and applicator in the full methods.
- Energy flux density: 0.25 mJ/mm².
- Pulse count: 3,000 per session.
- Repetition rate: 4 Hz.
- Schedule: one session weekly for four weeks.
- Configuration: the report identifies stand-off II; this designation is device specific.
These are research identifiers, not a self-contained treatment prescription. The listed settings do not establish suitability for an individual patient or transferability between generators.
Technique and Care Integration
Use a trauma-informed approach with explicit consent, privacy, draping, an appropriate chaperone policy and permission to pause or stop. Positioning must be comfortable and the contact method appropriate for the intended external tissue field.
Coordinate with gynaecology, pelvic health rehabilitation, pain care and psychosexual support as indicated. Pelvic floor overactivity should not be managed as though it were simply muscle weakness.[9]
Course of Care and Reassessment
Document baseline pain distribution, symptom triggers, functional interference and patient priorities. Reassess comfort throughout treatment and use consistent outcome measures after the course. Reference 6’s one-, four- and 12-week follow-ups provide research context rather than a mandatory clinical timetable.
Modify or stop care for persistent pain flares, new sensory changes, tissue injury or lack of meaningful benefit. New lesions, unexplained bleeding or a changing symptom pattern require examination and diagnostic review.
Safety and Further Education
Screen for infection, unexplained lesions, fragile or damaged tissue and pregnancy-related considerations before planning an intimate intervention. Do not treat undiagnosed vulvar pain as confirmed vulvodynia.
Review safety and contraindications · Explore professional training
Stress Urinary Incontinence***
Experimental Indication
Overview
Stress urinary incontinence is involuntary leakage associated with exertion, coughing or sneezing. Distinguish stress leakage from urgency incontinence, incomplete emptying and mixed symptoms. Assessment may include a bladder diary, examination, urinalysis, a cough stress test and residual urine measurement when indicated.[8],[10]
Treatment aims to reduce leakage and improve activity and quality of life. NICE recommends at least three months of supervised pelvic floor muscle training as first-line care for women with stress or mixed incontinence.[10] Shockwave research should not displace this established pathway.
Anatomy and Treatment Targeting
Relevant structures include the urethra, periurethral tissues, continence support mechanisms and pelvic floor. Study protocols have used external and transvaginal routes. These routes produce different exposure patterns and require different applicators, infection-control procedures and competencies.[8],[11]
Illustrative Protocol Framework
| Research source | Device / applicator | Reported parameters | Schedule and limitations |
|---|---|---|---|
| Lin et al, 2021[13] | DUOLITH SD1-TOP focused system with external application; verify the exact treatment-head configuration in the full methods | 0.25 mJ/mm²; 3,000 pulses; 3 Hz | Weekly treatment, assessed at four and eight weeks; later follow-up extended to six months. Not an intravaginal protocol. |
| Padoa et al, 2024[11] | MoreNovaFEM system with a study-specific vaginal probe | 0.10 mJ/mm²; 1,600 pulses; repetition rate not specified in the abstract | Twice weekly for four weeks; eight sessions. Not transferable to an external radial handpiece. |
These examples identify reported research. They do not provide a universal dose or establish approval for a particular device in a particular jurisdiction. The full methods, eligibility criteria and device instructions remain essential.
Technique and Care Integration
Internal treatment requires appropriately qualified clinicians, specific consent, compatible equipment and validated infection-control procedures. External and internal techniques should remain clearly distinguished in patient education and documentation.
Maintain appropriate pelvic floor rehabilitation and medical or urogynecological review. Evaluate prolapse, tissue changes and relevant surgical history where indicated. A device-based intervention should not delay established treatment options.
Course of Care and Reassessment
Record leakage frequency, activity triggers, pad use, a validated questionnaire such as ICIQ-UI SF and patient goals. Use pad testing when appropriate and document concurrent rehabilitation. Follow-up should assess both reported benefit and objective leakage where feasible.
Prespecify review points and stopping criteria. Reassess persistent symptoms instead of repeatedly adding sessions. Worsening voiding difficulty, recurrent infection, pain or bleeding warrants clinical review.
Safety and Further Education
The transvaginal trial reported possible procedure-related spotting, urinary tract infection and bacterial vaginosis.[11] Small studies cannot rule out uncommon harms or establish long-term safety. Pregnancy, infection, unexplained bleeding, recent surgery and implants require careful assessment under the relevant device instructions.
Read the contraindications resource · Explore professional education
Safety and Contraindications in Women’s & Pelvic Health
Suitability begins with diagnosis, a relevant medical and surgical history, tissue examination and review of the intended device and treatment route. Explain alternatives, uncertainty, expected costs and the option not to proceed.
ISMST lists a malignant tumour, fetus or pacemaker/defibrillator in the treatment field among contraindications for radial and low-energy focused techniques. High-energy focused treatment has additional restrictions, including significant coagulation disorders and lung tissue in the field.[1] These distinctions matter, particularly near the chest, abdomen and pelvis. They do not replace a complete device-specific screening process.
Additional assessment considerations include pregnancy, suspected infection or thrombosis, unexplained swelling, fragile tissue, bleeding risk, altered sensation, recent surgery, implants and undiagnosed lesions or bleeding. These findings do not all have the same status as absolute contraindications. Clarify the diagnosis and follow the manufacturer’s instructions and appropriate specialist guidance.
Document consent and monitor discomfort, redness, bruising, bleeding, symptom flares and any unexpected change. Internal procedures require additional attention to mucosal suitability and infection control. Studies reporting few adverse events do not establish that an application is risk free.[6],[11]
Seek prompt medical assessment for acute limb swelling, suspected infection, severe new pelvic pain, urinary retention, unexplained bleeding or concerning neurological symptoms. Do not use elective treatment to delay investigation.
Develop Your Clinical Reasoning in Women’s Health Shockwave Care
Build a more informed approach to acoustic technologies, clinical evidence and treatment planning with Wasabi Method’s professional education.
Explore the online course catalogue for relevant learning opportunities in device principles, patient selection, anatomy, safety, documentation and care integration. Check each course description for women’s health coverage, entry requirements and practical competencies. Education is intended for qualified healthcare professionals working within their own professional scope.
Medical Education Disclaimer
This material provides professional education, not an individual diagnosis or treatment prescription. Protocol examples describe published research and are not complete clinical instructions. Decisions require individual assessment, appropriate qualifications, professional judgment, current device instructions and compliance with applicable regulations and scope of practice. Findings from one population, device, treatment route or care setting cannot automatically be generalised to another. Experimental applications require transparent discussion of uncertainty and appropriate clinical or research governance.
References
- International Society for Medical Shockwave Treatment. ISMST recommendations: consensus statement on ESWT indications and contraindications; terms and definitions. Indications statement dated October 2016; terminology statement dated June 20, 2017. Accessed October 18, 2026. https://shockwavetherapy.org/ismst-recommendations/
- Tsai YL, I TJ, Chuang YC, Cheng YY, Lee YC. Extracorporeal shock wave therapy combined with complex decongestive therapy in patients with breast cancer-related lymphedema: a systemic review and meta-analysis. J Clin Med. 2021;10(24):5970. doi:10.3390/jcm10245970. https://doi.org/10.3390/jcm10245970
- Deng C, Wu Z, Cai Z, Zheng X, Tang C. Conservative medical intervention as a complement to CDT for BCRL therapy: a systematic review and meta-analysis of randomized controlled trials. Front Oncol. 2024;14:1361128. doi:10.3389/fonc.2024.1361128. https://doi.org/10.3389/fonc.2024.1361128
- Novo Rigueiro M, Bravo González M, Prado Moraña T, et al. Clinical, ultrasound, elastography and bioimpedance changes after radial extracorporeal shock wave therapy in patients with lipedema: a prospective within-patient study. Phlebology. Published online May 11, 2026. doi:10.1177/02683555261451555. https://doi.org/10.1177/02683555261451555
- Bruno A, Cilluffo M. Shockwave therapy in lipedema patients: a prospective study. Phlebology. 2026;41(1):58-67. doi:10.1177/02683555251343155. https://doi.org/10.1177/02683555251343155
- Hurt K, Zahalka F, Halaska M, Rakovicova I, Krajcova A. Extracorporeal shock wave therapy for treatment of vulvodynia: a prospective, randomized, double-blind, placebo-controlled study. Eur J Phys Rehabil Med. 2020;56(2):169-174. doi:10.23736/S1973-9087.20.05903-1. https://doi.org/10.23736/S1973-9087.20.05903-1
- Calafiore D, Marotta N, Curci C, et al. Efficacy of rehabilitative techniques on pain relief in patients with vulvodynia: a systematic review and meta-analysis. Phys Ther. 2024;104(7):pzae054. doi:10.1093/ptj/pzae054. https://doi.org/10.1093/ptj/pzae054
- Xi T, Jin M, Gao X. Efficacy of extracorporeal shock wave therapy for female stress urinary incontinence: a systematic review and meta-analysis. Transl Androl Urol. 2025;14(8):2185-2194. doi:10.21037/tau-2025-123. https://tau.amegroups.org/article/view/142383/html
- American College of Obstetricians and Gynecologists. Persistent vulvar pain. Committee Opinion No. 673. September 2016. Accessed October 18, 2026. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2016/09/persistent-vulvar-pain
- National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management. NICE guideline NG123. Published April 2, 2019. Accessed October 18, 2026. https://www.nice.org.uk/guidance/ng123/chapter/recommendations
- Padoa A, Levy E, Tsviban A, Tomashev R, Fligelman T. Low intensity extracorporeal shock wave therapy for female stress urinary incontinence using a vaginal probe: a single-blind, randomized-controlled trial. Continence. 2024;12(suppl):101351. Conference abstract presented October 23, 2024. doi:10.1016/j.cont.2024.101351. https://www.ics-eus.org/2024/abstract/9
- STORZ MEDICAL. Customised body and facial treatments with AWT acoustic waves. AWT4you. Accessed October 18, 2026. https://www.awt4you.com/en/body-treatments-acoustic-waves-awt-storz-medical.php
- Lin KL, Chueh KS, Lu JH, et al. Low intensity extracorporeal shock wave therapy as a novel treatment for stress urinary incontinence: a randomized-controlled clinical study. Medicina (Kaunas). 2021;57(9):947. doi:10.3390/medicina57090947. https://doi.org/10.3390/medicina57090947
Editorial Information
Author: Wasabi Method | SWSNA Medical reviewer: Adam Gavine, BHK, M.Chiro | Shockwave Trainer | International Medical Shockwave Advisor Medical review date: 10/2026 Source-check date: October 18, 2026
Editorial approach: Manufacturer-neutral interpretation of clinical research and professional guidance. Historical indication categories are distinguished from current evidence certainty and regulatory status. The experimental classifications for vulvodynia and stress urinary incontinence are editorial assessments for this page.
Disclosures: Wasabi Method provides commercial education and promotes related products or services through its website. The reviewer’s stated roles include shockwave training and advisory work. Manufacturer material is identified as commercial context and is not used as independent proof of clinical benefit. The transvaginal study in reference 11 reported manufacturer funding.
Wasabi Method | Clinical Knowledge. Practical Impact.
Explore professional shockwave education and the shockwave safety and contraindications resource. Wasabi Method’s resources support informed professional learning. They do not extend a practitioner’s licence, specialty or scope of practice.